X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/halozyme-to-report-first-quarter-2024-financial-and-operating-results-302124221.html
https://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-302072329.html
https://www.prnewswire.com/news-releases/halozyme-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-302066564.html
https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-302058060.html
https://www.fiercepharma.com/pharma/bristol-myers-unfolds-subcutaneous-opdivo-data-kidney-cancer-i-o-battle-heads-new-front
https://www.prnewswire.com/news-releases/halozyme-announces-takeda-received-european-commission-approval-for-hyqvia-co-formulated-with-enhanze-as-maintenance-therapy-for-chronic-inflammatory-demyelinating-polyneuropathy-cidp-302047182.html
https://www.prnewswire.com/news-releases/halozyme-announces-argenx-received-approval-in-japan-for-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-co-formulated-with-enhanze-for-generalized-myasthenia-gravis-302038081.html
https://ir.halozyme.com/news/news-details/2024/Halozyme-Announces-Takeda-Receives-FDA-Approval-for-HYQVIA-Co-formulated-with-ENHANZE-as-Maintenance-Therapy-in-Adults-with-Chronic-Inflammatory-Demyelinating-Polyneuropathy-CIDP/default.aspx
https://www.pharmaceutical-technology.com/news/roche-tecentriq-sc-ec-approval/?cf-view
https://www.prnewswire.com/news-releases/halozyme-to-host-investor-business-forum-and-long-term-outlook-call-302033655.html
Market Place
Share 
